Skip to content
Menu
Menu
Company
Company Profile
Management
Supervisory Board
Partners
Science
Pipeline
TCR-T Cells
MDG1015
Publications
Abstracts
End-to-End Platform
Overview
Target Screening
TCR Generation
TCR-T Therapy Optimization
Manufacturing/Scale-up & Process Improvement
Clinical Development
Investors & Media
Press & Material News Releases
Stock Information
Analyst Coverage
Shareholder Structure
Capital Measures
Reports & Presentations
Corporate Governance & Compliance
Events
Annual General Meeting
Investor Contact
E-mail Alerts
Careers
Contact
English
Deutsch
Menu
Company
Company Profile
Management
Supervisory Board
Partners
Science
Pipeline
TCR-T Cells
MDG1015
Publications
Abstracts
End-to-End Platform
Overview
Target Screening
TCR Generation
TCR-T Therapy Optimization
Manufacturing/Scale-up & Process Improvement
Clinical Development
Investors & Media
Press & Material News Releases
Stock Information
Analyst Coverage
Shareholder Structure
Capital Measures
Reports & Presentations
Corporate Governance & Compliance
Events
Annual General Meeting
Investor Contact
E-mail Alerts
Careers
Contact
English
Deutsch
Shareholder Structure
Shareholder structure as of 31 December 2022
1
Number of shares outstanding
24,562,658
Free float
2
92.99%
DJSMontana
3
3.45%
Shares held by Executive and Supervisory Board
4
3.56%
Based on last notification
Shareholding below 3%
Prof. Dr. Schendel indirectly holds 846,296 Medigene shares in her capacity as Managing Director of DJS Montana Holding GmbH, which all are directly allocated to Prof. Dr. Schendel.
see note #3, DJSMontana